Last reviewed · How we verify

NCT03574493: RESET

Rectal Surgery Evaluation Trial (RESET)

Completed Last updated 12 February 2025
What this trial tests

trial testing TME with LAR in Rectal Cancer in 1,098 participants. Completed in 31 December 2024.

Timeline
16 October 2018
Primary endpoint
31 December 2022
31 December 2024

Quick facts

Lead sponsorInstitut du Cancer de Montpellier - Val d'Aurelle
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,098
Start date16 October 2018
Primary completion31 December 2022
Estimated completion31 December 2024
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Institut du Cancer de Montpellier - Val d'Aurelle — full company profile →

Who can join

18 and older, any sex, with Rectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Total mesorectal excision (TME) is the standard of care for rectal cancer, which can be combined with low anterior resection (LAR) in patients with mid-to-low rectal cancer. The narrow pelvic space and difficulties in obtaining adequate exposure make surgeries technically challenging. Four techniques are used to perform the surgery: open laparotomy, laparoscopy, robot-assisted surgery, and transanal surgery. Comparative data for these techniques is required to provide clinical data on the surgical management of rectal cancers by surgery.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Robotic Surgery in Rectal Cancer: Potential, Challenges, and Opportunities.
    Liu G, Zhang S, Zhang Y, Fu X, et al · · 2022 · cited 41× · PMID 35438444 · DOI 10.1007/s11864-022-00984-y
  2. MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma.
    Sgarbura O, Gourgou S, Tosi D, Bakrin N, et al · · 2019 · cited 22× · PMID 31417958 · DOI 10.1515/pp-2019-0010
  3. A Prospective European Trial Comparing Laparotomy, Laparoscopy, Robotic-assisted, and Transanal Total Mesorectal Excision Procedures in High-risk Patients With Rectal Cancer: The RESET Trial.
    Rouanet P, Guerrieri M, Lemercier P, Balik E, et al · · 2026 · cited 8× · PMID 39263755 · DOI 10.1097/sla.0000000000006534
  4. 3D pelvimetry and biometric measurements: a surgical perspective for colorectal resections.
    Lorenzon L, Bini F, Landolfi F, Quinzi S, et al · · 2021 · cited 8× · PMID 33230658 · DOI 10.1007/s00384-020-03802-9
  5. Intraperitoneal Chemotherapy for Peritoneal Metastases: Technical Innovations, Preclinical and Clinical Advances and Future Perspectives.
    Christou N, Auger C, Battu S, Lalloué F, et al · · 2021 · cited 5× · PMID 33804167 · DOI 10.3390/biology10030225
  6. Robotic-Assisted Surgery for Rectal Cancer: An Expedited Summary of the Clinical Evidence.
    Ontario Health . · · 2024 · cited 1× · PMID 38645608

Verify or expand the search:

Other recruiting trials for Rectal Cancer

Currently open trials in the same condition.

Other Institut du Cancer de Montpellier - Val d'Aurelle trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03574493.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing